SCHEMBL17226019

SCHEMBL17226019

NOc1ccc(C(N)=O)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 18/20 0.70
PARP15 Q460N3 5/20 0.70
PARP4 Q9UKK3 2/20 0.70
PARP14 Q460N5 2/20 0.70
ALDH1A1 P00352 1/20 0.70
KMT2A Q03164 1/20 0.70
PARP16 Q8N5Y8 1/20 0.70
PARP11 Q9NR21 1/20 0.70
PARP2 Q9UGN5 4/20 0.64
PARP1 P09874 2/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
PARP3 Q9Y6F1 1/20 0.53
TNKS O95271 1/20 0.52
TNKS2 Q9H2K2 1/20 0.52
POLB P06746 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAPT P10636 1/20 0.50
TSHR P16473 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3137816 0.82 PARP10 (1.00) PARP10PARP15PARP4PARP14ALDH1A1
Terephthalamide SCHEMBL23774 0.81 PARP1 (0.71) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL436778 0.80 CA1 (0.60) PARP10PARP15ALDH1A1KMT2ACA1
SCHEMBL28095695 0.78 PARP10 (0.67) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL17888032 0.78 PARP10 (0.67) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL10915794 0.78 MAPT (0.67) ALDH1A1KMT2ACA1CA2POLB
SCHEMBL15259341 0.78 PARP10 (0.67) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL201761 0.78 PARP10 (1.00) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL20369059 0.78 PARP10 (0.67) PARP10PARP15PARP4PARP14ALDH1A1
SCHEMBL7138100 0.78 PARP10 (0.67) PARP10PARP15PARP4PARP14ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163488-A1 CONJUGATION METHOD INVOLVING A TRANSGLUTAMINASE AT THE FC REGION COMPRISING A TRIMMED N-GLYCAN BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) 2025-05-22 US disclosed
US-9174203-B2 Selective and efficient bifunctional and trifunctional nanoporous catalysts and methods of synthesis thereof PATENT INNOVATIONS LLC 2015-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163488-A1 CONJUGATION METHOD INVOLVING A TRANSGLUTAMINASE AT THE FC REGION COMPRISING A TRIMMED N-GLYCAN ENGASE, B3GAT3, FCGR2A PARP10 930/4885PARP15 511/4885PARP4 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.